Fig. 3From: Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialMutational landscapes of 96 patients with refractory /relapsed AML. CR complete remission, CRi CR with incomplete hematological recovery, PR partial remission, NR non-remission, MRD measurable residual disease, TFs transcription factorsBack to article page